143 related articles for article (PubMed ID: 33210444)
1. Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control.
Jessen S; Becker V; Rzeppa S; Backer V; Bengtsen KH; Hullstein I; Dehnes Y; Hostrup M
Drug Test Anal; 2021 Apr; 13(4):747-761. PubMed ID: 33210444
[TBL] [Abstract][Full Text] [Related]
2. Enantioselective disposition of (R)-salmeterol and (S)-salmeterol in urine following inhaled dosing and application to doping control.
Jacobson GA; Hostrup M; Narkowicz CK; Nichols DS; Haydn Walters E
Drug Test Anal; 2017 Aug; 9(8):1262-1266. PubMed ID: 28033454
[TBL] [Abstract][Full Text] [Related]
3. The salmeterol anomaly and the need for a urine threshold.
Jacobson GA; Hostrup M
Drug Test Anal; 2022 Jun; 14(6):997-1003. PubMed ID: 32314556
[TBL] [Abstract][Full Text] [Related]
4. Determination of salmeterol, α-hydroxysalmeterol and fluticasone propionate in human urine and plasma for doping control using UHPLC-QTOF-MS.
Sakellariou P; Petrou M; Lyris E; Tsivou M; Fragkaki A; Kiousi P; Angelis YS; Pistos C
Biomed Chromatogr; 2021 Aug; 35(8):e5114. PubMed ID: 33720401
[TBL] [Abstract][Full Text] [Related]
5. Formoterol concentrations in blood and urine: the World Anti-Doping Agency 2012 regulations.
Eibye K; Elers J; Pedersen L; Henninge J; Hemmersbach P; Dalhoff K; Backer V
Med Sci Sports Exerc; 2013 Jan; 45(1):16-22. PubMed ID: 22843108
[TBL] [Abstract][Full Text] [Related]
6. Beta2-Agonist Doping Control and Optical Isomer Challenges.
Jacobson GA; Fawcett JP
Sports Med; 2016 Dec; 46(12):1787-1795. PubMed ID: 27164986
[TBL] [Abstract][Full Text] [Related]
7. Enantioselective disposition of (R,R)-formoterol, (S,S)-formoterol and their respective glucuronides in urine following single inhaled dosing and application to doping control.
Jacobson GA; Hostrup M; Narkowicz CK; Nichols DS; Walters EH
Drug Test Anal; 2019 Jul; 11(7):950-956. PubMed ID: 30865387
[TBL] [Abstract][Full Text] [Related]
8. The influence of exercise and dehydration on the urine concentrations of salbutamol after inhaled administration of 1600 µg salbutamol as a single dose in relation to doping analysis.
Haase CB; Backer V; Kalsen A; Rzeppa S; Hemmersbach P; Hostrup M
Drug Test Anal; 2016 Jul; 8(7):613-20. PubMed ID: 26044066
[TBL] [Abstract][Full Text] [Related]
9. Urine concentrations of vilanterol and its metabolites, GSK932009 and GW630200, after inhalation of therapeutic and supratherapeutic doses.
Østergaard M; Jessen S; Hansen ESH; Backer V; Panchal T; Baldwin S; Daley-Yates P; Hostrup M
Drug Test Anal; 2023 May; 15(5):516-528. PubMed ID: 36610030
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of salmeterol.
Cazzola M; Testi R; Matera MG
Clin Pharmacokinet; 2002; 41(1):19-30. PubMed ID: 11825095
[TBL] [Abstract][Full Text] [Related]
11. Medical and pharmacological approach to adjust the salbutamol anti-doping policy in athletes.
Pillard F; Lavit M; Cances VL; Rami J; Houin G; Didier A; Rivière D
Respir Res; 2015 Dec; 16():155. PubMed ID: 26704899
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
[TBL] [Abstract][Full Text] [Related]
13. Quantitative detection of inhaled salmeterol in human urine and relevance to doping control analysis.
Deventer K; Pozo OJ; Delbeke FT; Van Eenoo P
Ther Drug Monit; 2011 Oct; 33(5):627-31. PubMed ID: 21912333
[TBL] [Abstract][Full Text] [Related]
14. Salmeterol undergoes enantioselective bronchopulmonary distribution with receptor localisation a likely determinant of duration of action.
Jacobson GA; Raidal S; Robson K; Narkowicz CK; Nichols DS; Walters EH
J Pharm Biomed Anal; 2018 May; 154():102-107. PubMed ID: 29544104
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers.
Soulele K; Macheras P; Karalis V
Biopharm Drug Dispos; 2017 Oct; 38(7):407-419. PubMed ID: 28374512
[TBL] [Abstract][Full Text] [Related]
16. The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A.
Manchee GR; Eddershaw PJ; Ranshaw LE; Herriott D; Park GR; Bayliss MK; Tarbit MH
Drug Metab Dispos; 1996 May; 24(5):555-9. PubMed ID: 8723736
[TBL] [Abstract][Full Text] [Related]
17. Quantitative detection of inhaled formoterol in human urine and relevance to doping control analysis.
Deventer K; Pozo OJ; Delbeke FT; Van Eenoo P
Drug Test Anal; 2012 Jun; 4(6):449-54. PubMed ID: 22447497
[TBL] [Abstract][Full Text] [Related]
18. Urine concentrations of repetitive doses of inhaled salbutamol.
Elers J; Pedersen L; Henninge J; Hemmersbach P; Dalhoff K; Backer V
Int J Sports Med; 2011 Aug; 32(8):574-9. PubMed ID: 21563035
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous quantitative determinations of fluticasone propionate and salmeterol xinafote in diskus inhalers.
Duran A; Dogan HN; Ulgen M
Drug Metab Lett; 2014; 8(1):31-5. PubMed ID: 25313021
[TBL] [Abstract][Full Text] [Related]
20. Assay validation for vilanterol and its metabolites in human urine with application for doping control analysis.
Panchal T; Baldwin S; Østergaard M; Hansen ESH; Backer V; Hostrup M; Daley-Yates P
Drug Test Anal; 2023 May; 15(5):495-505. PubMed ID: 36581315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
